Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
9/2/2024
Navigator Medicines Announces $100M Series A Financing and In-Licensin...
8/30/2024
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor...
8/30/2024
HUTCHMED Pulls Regulatory Submission for Takeda-Partnered Cancer Drug ...
8/30/2024
Virogin Biotech Won Chinese Breakthru Therapy Deisgnation for HCC Drug...
8/30/2024
NMPA Suspends Import, Sales and Use of Dr. Reddy's Atomoxetine Hcl Cap...
8/30/2024
CDE Issues the List of Reference Formulations for GQCE Studies (82nd B...
8/30/2024
Recent Executive Moves
8/30/2024
Regional Price Differences of Medical Services: Evidence from China (B...
8/29/2024
Pharmaceutical Patent Disputes in China | The Nuances of "Offer to Sel...
8/29/2024
CDE Solicits Comments on Draft of the Technical Guidelines for Non-Cli...
8/29/2024
U.S. Government Funding Yields Over 1,000 Patents for China-Based Rese...
8/28/2024
CDE Solicits Comments on the Technical Guidelines for Clinical Develop...
8/28/2024
CDE Solicits Comments on the Technical Guidelines for Non-Clinical Eff...
8/28/2024
CDE Solicits Comments on the Technical Guidelines for Clinical Trials ...
8/28/2024
CDE Solicits Comments on the Technical Guidelines for Clinical Trials ...
8/28/2024
Mundipharma Fails to Sell China Unit for the Second Time Amidst High V...
8/27/2024
NHSA Issues the List of Drugs Passing Preliminary Form Evaluation for ...
8/27/2024
Legend Biotech Wins Chinese Approval of CAR-T Carvykti (Cilta-cel)
8/27/2024
Sanofi Suspends Supply and Sale of Flu Vaccine in China
8/27/2024
BrightGene Announces Positive Phase II Results for Diabetes Drug BGM05...
8/27/2024
Hengrui Secures Chinese Approval of IL-17A mAb, Vunakizumab
8/27/2024
Duality Biothera Seeks Hong Kong IPO to Advance BioNTech-Collaborated ...
8/27/2024
China Proposed New Anti-Monopoly Guidelines for the Pharmaceutical Sec...
8/26/2024
UCB Sells Chinese Neurology and Allergy Business for $680M
8/26/2024
Akeso Biopharma Registers New Phase III Clinical Trial for AK112 in Ch...
8/26/2024
BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/S...
8/26/2024
CDE Solicits Comments on Draft Implementation Suggestions and Chinese ...
8/26/2024
CDE Solicits Public Comments on the Guidelines for Writing Clinical-Re...
8/26/2024
CDE Solicits Public Comments on the Technical Guidelines for Pharmaceu...
8/26/2024
CDE Solicits Public Comments on the Technical Guidelines for Pharmaceu...
Page:
51
/
774
Total number of articles:
23207
:
[First]
[<<]
[49]
[50]
[51]
[52]
[53]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit